Editorial: New and emerging lipid-lowering therapies for reducing cardiovascular risk: beyond statins.
作者信息
Luo Fei, Yu Liqing, Xian Xunde, Shan Bo, Das Avash
机构信息
Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
School of Medicine, University of Maryland, Baltimore, MD, United States.
出版信息
Front Cardiovasc Med. 2024 Jan 15;11:1364170. doi: 10.3389/fcvm.2024.1364170. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: New and emerging lipid-lowering therapies for reducing cardiovascular risk: beyond statins.社论：降低心血管风险的新型及新兴降脂疗法：超越他汀类药物。
Front Cardiovasc Med. 2024 Jan 15;11:1364170. doi: 10.3389/fcvm.2024.1364170. eCollection 2024.
2
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.降低低密度脂蛋白胆固醇（LDL-C）在动脉粥样硬化性心血管疾病预防中的重要性：降得越低、维持时间越长越好。
Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun.
3
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.对经基因确诊的家族性高胆固醇血症患者进行第一代和第二代他汀类药物治疗，然后再使用 PCSK9 单克隆抗体进行长期随访。
Atherosclerosis. 2020 Sep;308:6-14. doi: 10.1016/j.atherosclerosis.2020.07.006. Epub 2020 Jul 29.
4
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
5
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估：临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
6
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.靶向低密度脂蛋白胆固醇的进展：前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂及其他。
Am J Prev Cardiol. 2024 Jun 25;19:100701. doi: 10.1016/j.ajpc.2024.100701. eCollection 2024 Sep.
7
A Clinical Guide to Combination Lipid-Lowering Therapy.《联合降脂治疗临床指南》
Curr Atheroscler Rep. 2018 Mar 7;20(4):19. doi: 10.1007/s11883-018-0721-2.
8
Lipid-lowering Therapies in Myositis.肌炎的降脂治疗。
Curr Rheumatol Rep. 2020 Aug 26;22(10):70. doi: 10.1007/s11926-020-00942-3.
9
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol.靶向前蛋白转化酶枯草溶菌素9及其他靶点以管理低密度脂蛋白胆固醇
J Clin Med. 2023 Aug 2;12(15):5082. doi: 10.3390/jcm12155082.
引用本文的文献
1
A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II.高胆固醇血症管理最新方法的全面综述：传统治疗与新型治疗的比较分析：第二部分
Pharmaceuticals (Basel). 2025 Aug 1;18(8):1150. doi: 10.3390/ph18081150.
本文引用的文献
1
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022.2007 年至 2022 年 PCSK9 抑制剂的文献计量分析。
Front Endocrinol (Lausanne). 2023 Nov 29;14:1218968. doi: 10.3389/fendo.2023.1218968. eCollection 2023.
2
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.依洛尤单抗治疗纯合子家族性高胆固醇血症患者的疗效、安全性和耐受性：ORION-5 随机临床试验结果。
Circulation. 2024 Jan 30;149(5):354-362. doi: 10.1161/CIRCULATIONAHA.122.063460. Epub 2023 Oct 18.
3
Correlation between serum soluble ASGR1 concentration and low-density lipoprotein cholesterol levels: a cross-sectional study.血清可溶性 ASGR1 浓度与低密度脂蛋白胆固醇水平的相关性：一项横断面研究。
Lipids Health Dis. 2023 Sep 4;22(1):142. doi: 10.1186/s12944-023-01910-3.
4
Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3.家族性高胆固醇血症：高危人群面临的挑战：美国心脏病学会焦点研讨会1/3
J Am Coll Cardiol. 2023 Apr 25;81(16):1621-1632. doi: 10.1016/j.jacc.2023.02.038.
5
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.ANGPTL3 抑制、血脂异常与心血管疾病。
Trends Cardiovasc Med. 2024 May;34(4):215-222. doi: 10.1016/j.tcm.2023.01.008. Epub 2023 Feb 5.
6
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.用于降低 LDL 胆固醇和载脂蛋白 B 的新出现的治疗方法：JACC 焦点研讨会 1/4。
J Am Coll Cardiol. 2021 Mar 30;77(12):1564-1575. doi: 10.1016/j.jacc.2020.11.079.
7
Evinacumab for Homozygous Familial Hypercholesterolemia.依维那库单抗用于纯合子家族性高胆固醇血症
N Engl J Med. 2021 Feb 11;384(6):e17. doi: 10.1056/NEJMc2033612.
8
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
9
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
10
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
Zotero 插件